Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review
(2024)
Journal Article
Introduction
The use of Janus kinase inhibitors (JAKis) in immune-mediated inflammatory diseases (IMIDs) beyond licence is expanding rapidly. The aim of this scoping review was to identify and present the available evidence on the efficacy of JAKis...
Read More about Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review.